Germany · Delayed Price · Currency is EUR Heidelberg Pharma AG Earnings Call Transcripts
Fiscal Year 2025
-
Strategic refocus on HDP-101 after a major partner delay led to cost reductions and a 75% workforce cut. Cash runway now extends to mid-2027, with promising clinical results for HDP-101 and new partnerships advancing. FY2025 saw higher R&D costs and a net loss of EUR 42.3 million.
-
HDP-101, a novel ADC for multiple myeloma, shows strong efficacy and a favorable safety profile in heavily pretreated patients, with rapid and deep responses in the highest dose cohort. Fast track designation was granted, and development plans target both post-BCMA and high-risk populations.
-
Announced a strategic refocus on HDP-101 and major cost reductions after a delayed $70M milestone payment tied to TLX250-CDx FDA approval. HDP-101 shows strong clinical promise, while other programs are paused or scaled back. Cash runway is extended to mid-2026.
-
HDP-101, an amanitin-based ADC targeting BCMA, shows strong efficacy and a favorable safety profile in heavily pretreated multiple myeloma patients, including durable complete remissions. Dose optimization has mitigated early thrombocytopenia, and phase II development is imminent.
-
A novel ADC platform using amanitin shows strong preclinical and early clinical efficacy in drug-resistant cancers, with a lead program in multiple myeloma achieving durable remissions and a favorable safety profile. Financially, the company is well-funded through royalty deals and strategic partnerships, with key milestones expected in 2024 and 2025.
Fiscal Year 2024
-
Strong clinical progress with HDP-101 and robust financial position from non-dilutive royalty financing extend funding into 2027. TLX250-CDx advances to FDA priority review, and multiple ADC programs progress in pipeline.